Catalyst Event
Sanofi (SNY) · Other
From KEDI Tesla Fixed Tech100 Index (KTSLT100)
5/28/2026, 12:00:00 AM
The U.S. FDA granted Priority Review on May 28, 2026, to the New Drug Application for venglustat for the treatment of type 3 Gaucher disease, with a target action date of November 25, 2026.
Korean Translation
미국 FDA, 2026년 5월 28일 제3형 고셔병 치료제 벤글루스탯의 신약 허가 신청에 대해 우선 심사 자격을 부여함. 목표 심사 기일은 2026년 11월 25일임.
Related Recent Events
Microchip Technology Inc (MCHP) · Earnings Release
Next quarterly earnings for Q1 2027 are expected to be released around August 6, 2026, expected. Low impact is estimated as this is a routine scheduling announcement.
8/6/2026, 12:00:00 AM
AppLovin Corporation (APP) · Earnings Release
AppLovin's Q2 2026 earnings release is expected around August 5, 2026, based on past reporting schedules expected. Low impact estimated as the announcement of a date typically precedes the actual market-moving results.
8/5/2026, 12:00:00 AM
Advanced Micro Devices Inc (AMD) · Earnings Release
Q2 2026 earnings release and conference call scheduled.
8/4/2026, 12:00:00 AM
Super Micro Computer Inc (SMCI) · Earnings Release
The Q4 2026 earnings release is scheduled for August 4, 2026. Low importance is estimated as no market reaction has occurred yet for this future date, expected.
8/4/2026, 12:00:00 AM
Comcast Corp (CMCSA) · Earnings Release
Comcast's Q2 2026 earnings release on July 30, 2026 scheduled. Medium importance is estimated as earnings reports often impact stock prices.
7/30/2026, 12:00:00 AM
KLA Corp (KLAC) · Earnings Release
Fiscal Q4 2026 earnings release on July 30, 2026, is expected to have a medium importance impact on the stock price, scheduled.
7/30/2026, 12:00:00 AM